B7-1 but not CD28, is crucial for the maintenance of the CD4+ T cell responses in human leprosy

被引:0
|
作者
Schlienger, K
Uyemura, K
Jullien, D
Sieling, PA
Rea, TH
Linsley, PS
Modlin, RL
机构
[1] Univ Calif Los Angeles, Sch Med, Div Dermatol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA
[3] Univ So Calif, Sch Med, Dermatol Sect, Los Angeles, CA 90095 USA
[4] Bristol Myers Squibb Pharmaceut Res Inst, Seattle, WA 98121 USA
来源
JOURNAL OF IMMUNOLOGY | 1998年 / 161卷 / 05期
关键词
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We used human leprosy as a model to compare patterns of costimulatory molecule expression in respect to the clinical/immunologic spectrum of disease. We found that B7-1, B7-2, and CD28 transcripts dominated in tuberculoid leprosy patients, who have potent T cell responses to Mycobacterium leprae. In contrast, CTLA-4 was more strongly expressed in lesions from lepromatous patients, who manifest specific T cell anergy to the leprosy bacterium. T cell clones from tuberculoid lesions were CD4(+)CD28(+) or CD4(+)CD28(-), and T cell clones from lepromatous lesions were predominantly CD8(+)CD28(-). The M. leprae-specific recall response of CD4(+) T cell clones from tuberculoid lesions was blocked by anti-B7-1 mAb, but not by anti-B7-2 mAb or CTLA-Ig. However, anti-CD28 and anti-CTLA-4 mAbs did not block activation of clones from tuberculoid lesions, suggesting that B7-1 may utilize another costimulatory pathway. Peripheral blood T cell responses in the lepromatous form were strongly regulated by CD28 during T cell activation, in contrast to the tuberculoid form. Thus, B7-1 costimulation could play a role in maintaining a strong immune response to the pathogen.
引用
收藏
页码:2407 / 2413
页数:7
相关论文
共 50 条
  • [31] Profound down-modulation of adaptive tolerant CD4+ T cell proliferation in the absence of CD28
    Inobe, M
    Schwartz, RH
    FASEB JOURNAL, 2005, 19 (04): : A908 - A908
  • [32] CD28 signaling is also involved in the CD4+ T cell tolerance reaction to harmless exogenous antigen
    Hegemann, A.
    Mettke, E.
    Reeg, N.
    Yang, Y.
    Mages, H. W.
    Gurka, S.
    Kroczek, R. A.
    IMMUNOLOGY, 2012, 137 : 419 - 420
  • [33] Role of CD40 ligand and CD28 in induction and maintenance of antiviral CD8+ effector T cell responses
    Andreasen, SO
    Christensen, JE
    Marker, O
    Thomsen, AR
    JOURNAL OF IMMUNOLOGY, 2000, 164 (07): : 3689 - 3697
  • [34] Aurora B regulates CD4 T cell expansion mediated by CD28 cosignals
    Song, Jianxun
    Tatsuka, Masaaki
    Croft, Michael
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S175 - S175
  • [35] Memory CD8+ T cell responses require CD28 costimulation
    Borowski, Annie B.
    Boesteanu, Alina
    Dolfi, Douglas V.
    Mueller, Yvonne M.
    Carafides, Caterina
    Katsikis, Peter D.
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S184 - S184
  • [36] IDENTIFICATION OF RESIDUES IN THE V-DOMAIN OF CD80 (B7-1) IMPLICATED IN FUNCTIONAL INTERACTIONS WITH CD28 AND CTLA4
    FARGEAS, CA
    TRUNEH, A
    REDDY, M
    HURLE, M
    SWEET, R
    SEKALY, RP
    JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (03): : 667 - 675
  • [37] Anomalous expression of costimulatory molecules B7-1, B7-2 and CD28 in primary biliary cirrhosis
    Spengler, U
    Leifeld, L
    Braunschweiger, I
    Dumoulin, FL
    Lechmann, M
    Sauerbruch, T
    JOURNAL OF HEPATOLOGY, 1997, 26 (01) : 31 - 36
  • [38] CD28 downregulation on CD4+ T cells is associated with age of kidney transplant recipient
    Kusztal, Mariusz
    Kosmaczewska, Agata
    Magott-Procelewska, Maria
    Frydecka, Irena
    Ciszak, Lidia
    Bocko, Dorota
    Patrzalek, Dariusz
    Klinger, Marian
    TRANSPLANT INTERNATIONAL, 2008, 21 (07) : 661 - 668
  • [39] The HIV-1 accessory proteins Nef and Vpu downregulate total and cell surface CD28 in CD4+ T cells
    Emily N. Pawlak
    Brennan S. Dirk
    Rajesh Abraham Jacob
    Aaron L. Johnson
    Jimmy D. Dikeakos
    Retrovirology, 15
  • [40] Cell surface CD28 levels define four CD4+ T cell subsets:: Abnormal expression in rheumatoid arthritis
    Salazar-Fontana, LI
    Sanz, E
    Mérida, I
    Zea, A
    Sanchez-Atrio, A
    Villa, L
    Martínez, C
    de la Hera, A
    Alvarez-Mon, M
    CLINICAL IMMUNOLOGY, 2001, 99 (02) : 253 - 265